Mallinckrodt to buy Sucampo for $1.2 billion | January 8, 2018 Issue - Vol. 96 Issue 2 | Chemical & Engineering News
Volume 96 Issue 2 | p. 10 | Concentrates
Issue Date: January 8, 2018

Mallinckrodt to buy Sucampo for $1.2 billion

Department: Business
Keywords: Pharmaceuticals, Mallinckrodt, Sangamo

Mallinckrodt has agreed to acquire Sucampo Pharmaceuticals, a Rockville, Md.-based drugmaker, for $1.2 billion. With the deal, Mallinckrodt will pick up two approved drugs: Amitiza, a treatment for various bowel diseases with 2016 sales of $456 million, and Rescula, a treatment for ocular hypertension and glaucoma with annual sales of about $9 million. Mallinckrodt CEO Mark Trudeau says the deal also bolsters the company’s rare disease drug pipeline with VTS-270, in development for Niemann-Pick disease type C1, and CPP-1X/sulindac, in development for familial adenomatous polyposis.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment